UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-Q

for the transition period from                        to                       .

Commission File Number  001-13543

ANGEION CORPORATION

(Exact name of registrant as specified in its charter)

350 Oak Grove Parkway, Saint Paul, Minnesota 55127-8599

(Address of principal executive offices)

Registrant’s telephone number, including area code: (651) 484-4874

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

As of June 13, 2008, the Company had outstanding 4,089,803 shares of Common Stock, $0.10 par value.

TABLE OF CONTENTS

2

PART I – FINANCIAL INFORMATION

Item 1.  Financial Statements.

ANGEION CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

April 30, 2008 and October 31, 2007

(in thousands except share and per share data)

See accompanying notes to consolidated financial statements.

3

ANGEION CORPORATION AND SUBSIDIARIES

Consolidated Statements of Earnings

(unaudited, in thousands except per share amounts)

See accompanying notes to consolidated financial statements.

4

ANGEION CORPORATION AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(unaudited, in thousands)

See accompanying notes to consolidated financial statements.

5

ANGEION CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.                                      Basis of Presentation and Description of Business

Angeion Corporation (the “Company”) through its Medical Graphics Corporation subsidiary, designs and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics and New Leaf brand and trade names.  These cardiorespiratory diagnostic systems have a wide range of applications in healthcare, wellness and health and fitness.

The consolidated balance sheet as of April 30, 2008, the consolidated statements of earnings for the three and six months ended April 30, 2008 and 2007, and cash flows for the six months ended April 30, 2008 and 2007, and the related information presented in these notes have been prepared by management in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, without audit.  Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles for complete financial statements.  In the opinion of management, all adjustments considered necessary for a fair presentation of results have been included.  The consolidated balance sheet at October 31, 2007 was derived from the audited consolidated financial statements as of that date.  Operating results for the three and six months ended April 30, 2008 are not necessarily indicative of the results that may be expected for the year ending October 31, 2008.  For further information, refer to the consolidated financial statements and notes thereto included in Angeion Corporation’s Annual Report on Form 10-K for the year ended October 31, 2007.

Comprehensive income (loss) is a measure of all non-owner changes in shareholders’ equity and includes items such as net income, certain foreign currency translation items, minimum pension liability adjustments and changes in the value of available-for-sale securities.  For the three and six months ended April 30, 2008 and 2007, comprehensive income (loss) for Angeion Corporation was equivalent to net income (loss) as reported.

Preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities made in the consolidated financial statements and accompanying notes.  Actual results could differ from those estimates.  Estimates include accounts receivable, product warranty and inventory reserves, and depreciable lives of property, equipment and intangible assets.

2.                                      Revenue Recognition

In accordance with the SEC’s Staff Accounting Bulletin No. 104, “Revenue Recognition,” the Company recognizes revenue when persuasive evidence of an arrangement exists, transfer of title has occurred or services have been rendered, the selling price is fixed or determinable and collectability is reasonably assured.  The Company’s products are sold for cash or on credit terms requiring payment based on the shipment date.  Credit terms can vary between customers due to many factors, but are generally 30-60 days.  Revenue, net of discounts, is recognized upon shipment or delivery to customers in accordance with written sales terms.  Standard sales terms do not include customer acceptance conditions, future credits, rebates, price protection or general rights of return.  The terms of sales to both domestic customers and international distributors are identical.  In instances when a customer order specifies final acceptance of the system, revenue is deferred until all customer acceptance criteria have been met.  Estimated warranty obligations are recorded upon shipment.

6

Service contract revenue is based on a stated contractual rate and is deferred and recognized ratably over the service period, which is typically from one to four years.  In accordance with paragraph 4 of the Emerging Issues Task Force abstract 00-21, “Revenue Arrangements with Multiple Deliverables,” the Company applies Financial Accounting Standards Board (“FASB”) Technical Bulletin No. 90-1 to service contract revenue.  Deferred income associated with service contracts and supplies was $2,221,000 and $2,120,000 at April 30, 2008 and October 31, 2007, respectively. Revenue from installation and training services provided to customers is deferred until the service has been performed.  The amount of deferred installation and training revenue was $350,000 and $365,000 at April 30, 2008 and October 31, 2007, respectively.

When a sale involves multiple deliverables, such as equipment, installation services and training, the amount of the consideration from an arrangement is allocated to each respective element based on the residual method and recognized as revenue when revenue recognition criteria for each element is met.  Consideration allocated to delivered equipment is equal to the total arrangement consideration less the fair value of installation and training.  The fair value of installation and training services is based on specific objective evidence, including third-party invoices.

The Company had one customer that accounted for 23.8% of revenues for both the three and six months ended April 30, 2007.  No customer accounted for more than 10% of revenues for the three and six months ended April 30, 2008.

Advance Payments from Customers

The Company typically does not receive advance payments from its customers in connection with the sale of its products.  The Company occasionally enters into an arrangement under which a customer agrees to purchase a large quantity of product that is to be delivered over a period of time.  Depending on the size of these arrangements, the Company may negotiate an advance payment from these customers.  Advance payments from customers aggregating $70,000 and $97,000 as of April 30, 2008 and October 31, 2007, respectively, are included in deferred income on the consolidated balance sheets.  Revenue recognition for customer orders that include advance payments is consistent with the Company’s revenue recognition policy described above.

3.                                      New Accounting Pronouncements

In May 2008, the FASB issued Statements of Financial Standards No. 162 (SFAS 162), “The Hierarchy of Generally Accepted Accounting Principles.” SFAS 162 is intended to improve financial reporting by identifying a consistent framework, or hierarchy, for selecting accounting principles to be used in preparing financial statements that are presented in conformity with U.S. generally accepted accounting principles (GAAP) for nongovernmental entities.

Prior to the issuance of SFAS 162, GAAP hierarchy was defined in the American Institute of Certified Public Accountants (AICPA) Statement on Auditing Standards No. 69 (SAS 69), “The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles.” SAS 69 has been criticized because it is directed to the auditor rather than the entity. SFAS 162 addresses these issues by establishing that the GAAP hierarchy should be directed to entities because it is the entity (not its auditor) that is responsible for selecting accounting principles for financial statements that are presented in conformity with GAAP.

SFAS 162 is effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board Auditing amendments to AU Section 411, “The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles.”  The Company does not expect SFAS 162 to have a material effect on its consolidated financial statements.

7

During May 2008, the FASB issued SFAS 163, “Accounting for Financial Guarantee Insurance Contracts.”  SFAS 163 provides enhanced guidance on the recognition and measurement to be used to account for premium revenue and claim liabilities and related disclosures and is limited to financial guarantee insurance (and reinsurance) contracts, issued by enterprises included within the scope of FASB Statement No. 60, “Accounting and Reporting by Insurance Enterprises”.  SFAS 163 also requires that an insurance enterprise recognize a claim liability prior to an event of default when there is evidence that credit deterioration has occurred in an insured financial obligation.  SFAS 163 is effective for financial statements issued for fiscal years and interim periods beginning after December 15, 2008, with early application not permitted.  The Company does not expect SFAS 163 to have an impact on its consolidated financial statements.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“SFAS No. 157”), which is effective for fiscal years beginning after November 15, 2007 and for interim periods within those years.  This statement defines fair value, establishes a framework for measuring fair value and expands the related disclosure requirements.  The Company is currently evaluating the impact of SFAS No. 157 on its consolidated financial statements.

In February 2008, the FASB issued FASB Staff Position (FSP) Financial Accounting Standard (FAS) 157-1, Application of FASB Statement No. 157 to FASB Statement No. 13 and Its Related Interpretive Accounting Pronouncements That Address Leasing Transactions , and FSP FAS 157-2, Effective Date of FASB Statement No. 157 . FSP FAS 157-1 removes leasing from the scope of SFAS No. 157, “Fair Value Measurements.” FSP FAS 157-2 delays the effective date of SFAS No. 157 from 2008 to 2009 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). See SFAS No. 157 discussion above.

In December 2007, the FASB issued SFAS No. 141 (revised 2007) Business Combinations (SFAS No. 141(R)). SFAS No. 141(R) retains the fundamental requirements of the original pronouncement requiring that the purchase method be used for all business combinations. SFAS No. 141(R) defines the acquirer as the entity that obtains control of one or more businesses in the business combination, establishes the acquisition date as the date that the acquirer achieves control and requires the acquirer to recognize the assets acquired, liabilities assumed and any noncontrolling interest at their fair values as of the acquisition date. SFAS No. 141(R) also requires that acquisition-related costs be recognized separately from the acquisition. SFAS No. 141(R) is effective for fiscal years beginning on or after December 15, 2008. The Company is currently assessing the impact of SFAS No. 141(R) on its consolidated financial statements.

In December 2007, the FASB issued Statement No. 160, Noncontrolling Interests in Consolidated Financial Statements (SFAS No. 160). SFAS No. 160 clarifies that a noncontrolling interest in a subsidiary should be reported as equity in the consolidated financial statements. Consolidated net income should include the net income for both the parent and the noncontrolling interest with disclosure of both amounts on the consolidated statement of income. The calculation of earnings per share will continue to be based on income amounts attributable to the parent. SFAS No. 160 is effective for fiscal years beginning on or after December 15, 2008. The Company is currently assessing the impact of SFAS No. 160 on its consolidated financial statements.

4.                                      Share-Based Compensation and Stock Options

Effective November 1, 2006, the Company adopted the provisions of FASB Statement No. 123 (revised 2004), Share-Based Payment (“SFAS No. 123R”).  Under the fair value recognition provisions of SFAS No. 123R, the Company measures stock-based compensation cost at the grant date based on the

8

fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period.  The Company elected the modified-prospective method of adopting SFAS No. 123R, under which prior periods are not retroactively restated.  The provisions of SFAS No. 123R apply to awards granted, modified or cancelled after the November 1, 2006 effective date.  There were no non-vested awards outstanding on the effective date for SFAS No. 123R.  Total share-based compensation expense included in the Company’s statement of earnings for the three and six months ended April 30, 2008 was $106,000 and $217,000, respectively, compared to $4,000 and $7,000 for the three and six months ended April 30, 2007, respectively.

Stock Options

Under the Angeion Corporation 2002 Stock Option Plan (the “2002 Plan”), the Company had reserved 800,000 shares of its common stock for issuance upon exercise of stock options.  As of April 30, 2008, options for 800,000 shares had been granted, 426,850 shares had been issued upon exercise of options, 950 were forfeited and options to purchase 372,200 shares remained outstanding.  In connection with our adoption of the 2007 Stock Incentive Plan described below, the 2002 Plan was amended to provide that no new options could be granted under the 2002 Plan.

At a Special Meeting of Shareholders held on August 22, 2007, the shareholders approved the Angeion Corporation 2007 Stock Incentive Plan (the “2007 Plan”) and reserved 250,000 shares of its common stock for issuance upon exercise of stock options under the 2007 Plan.  As of April 30, 2008, options for 226,420 shares were outstanding and 23,580 shares were available for future grant.

At the 2008 Annual Meeting of Shareholders held on May 20, 2008, the shareholders approved an amendment to the 2007 Plan that increased the authorized shares of common stock for issuance upon exercise of stock options by 300,000 to a total of 550,000 shares.

The 2007 Plan and 2002 Plan both provide that incentive stock options and nonqualified stock options to purchase shares of common stock may be granted at prices determined by the Compensation Committee, except that the purchase price of incentive stock options may not be less than the fair market value of the stock at date of grant.  Under the 2007 Plan, all options expire no later than seven years from the grant date while under the 2002 Plan, all options expire no later than ten years from the grant date.  Options under both plans are subject to various vesting schedules.

9

The following table summarizes information concerning stock options outstanding as of April 30, 2008:

The total intrinsic value of options exercised during the three and six months ended April 30, 2008 was $0.  The total intrinsic value of options outstanding and exercisable at April 30, 2008 was $836,000 and $789,000, respectively, which was calculated using the closing stock price as of April 30, 2008 less the exercise price of in-the-money options.  The Company issues new shares when stock options are exercised.  There was no cash received from the exercise of stock options or related tax benefits recognized for the three and six month period ended April 30, 2008.  Unrecognized compensation expense related to outstanding stock options as of April 30, 2008 was $1,014,000 and is expected to be recognized over a weighted average period of 2.49 years and will be adjusted for any future changes in estimated forfeitures.

The following table presents the statement of earnings classification of pre-tax share-based compensation expense recognized for the three and six months ended April 30, 2008:

Valuation Assumptions

The Company uses the Black-Scholes option-pricing model (“Black-Scholes model”) to determine the fair value of stock options as of the grant date.  The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company’s stock price and expected dividends.

10

Employee Stock Purchase Plan

The Angeion Corporation 2003 Employee Stock Purchase Plan (“Stock Plan”) allows participating employees to purchase shares of the Company’s common stock at a discount through payroll deductions.  The Stock Plan is available to all employees subject to certain eligibility requirements.  Terms of the Stock Plan provide that participating employees may purchase the Company’s common stock on a voluntary after tax basis.  Historically, employees could purchase the Company’s common stock at a price that is no less than the lower of 85% of the fair market value of one share of common stock at the beginning or end of each stock purchase period or phase.  The Company increased the price at which common stock may be purchased to 95% of the market value effective January 1, 2007.  The Stock Plan is carried out in six-month phases, with phases beginning on January 1 and July 1 of each calendar year.  For the phase that ended on December 31, 2007, employees purchased 1,348 shares at a price of $7.81 per share.  As of April 30, 2008, the Company has withheld approximately $7,020 from employees participating in the phase that began on January 1, 2008.  At April 30, 2008, approximately 69,085 shares of common stock were available for future purchase under the Stock Plan.

5.                                      Inventories

Inventories consisted of the following at April 30, 2008 and October 31, 2007:

6.                                      Intangible Assets and Goodwill

Intangible assets consisted of the following at April 30, 2008 and October 31, 2007:

The intangible assets are being amortized using the straight-line method over the estimated useful lives of the assets that range from three to ten years.  Amortization expense was $364,000 and $385,000 for the six months ended April 30, 2008 and 2007, respectively.  If the Company continues to utilize pre-emergence bankruptcy net operating loss carry forwards, the Company will further reduce the carrying cost of its developed technology until the net carrying cost of these assets is zero.  To the extent that utilization of these NOLs reduces the cost of developed technology, future amortization expense will be reduced.

11

Estimated amortization expense for each of the succeeding fiscal years based on the intangible assets as of April 30, 2008, which does not reflect the possible reduction discussed above, is as follows:

The Company did not realize any pre-bankruptcy tax benefits for the six months ended April 30, 2008.   Therefore, there were no non-amortization changes in the cost of intangible assets from October 31, 2007.

7.                                      Warranty Reserve

Sales of the Company’s equipment are subject to a warranty obligation.  Equipment warranties typically extend for a period of twelve months from the date of installation.  Standard warranty terms are included in customer contracts.  Under the terms of these warranties, the Company is obligated to repair or replace any components or assemblies that it deems defective in workmanship or materials.  The Company reserves the right to reject warranty claims where it determines that failure is due to normal wear, customer modifications, improper maintenance or misuse.  The Company maintains a warranty reserve that reflects the estimated expenses that it will incur to honor the warranties on its products.  The Company adjusts the warranty reserve based on the number and type of equipment that is subject to warranty, adjusted for the remaining months of warranty coverage.  The warranty reserve adjustment reflects the Company’s historical warranty experience based on type of equipment.  Warranty provisions and claims for the six months ended April 30, 2008 and 2007 were as follows:

8.                                      Earnings (Loss) per Share

Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average shares outstanding during the reporting period.  Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that in computing income per share the weighted average shares outstanding are increased to include additional shares from the assumed exercise of stock options or warrants, if dilutive.  The number of additional shares is calculated by assuming that outstanding stock options or warrants were exercised and that the proceeds from the exercise were used to acquire shares of common stock at the average market price during the reporting period.

The Company had 142,870 warrants outstanding at April 30, 2007 to purchase shares of its common stock.  There were no warrants that remained outstanding at April 30, 2008 as all unexercised warrants expired by their terms on October 31, 2007.  The Company also had options outstanding at April 30, 2008 and 2007 to purchase 598,620 and 398,286 shares, respectively, of its common stock.  As a

12

result of the net loss in the first and second quarters 2008, the outstanding stock options were considered antidilutive and, therefore, were excluded from diluted earnings (loss) per share.

Shares used in the earnings (loss) per share computations are as follows:

9.                                      Income Taxes

The Company has recorded a provision for taxes from operations of $0 and $314,000 for the three months ended April 30, 2008 and 2007, respectively.  The Company has not recognized the tax benefit generated by the year-to-date loss in light of the uncertainty surrounding the Company’s level of profitability for the balance of fiscal 2008 given, among other things, the lower expectations of clinical research revenues and the timing and success of new product introductions.  This assessment was made in a manner consistent with FASB Statement No. 109, Accounting for Income Taxes.  For the quarter ended April 30, 2007, the provision for taxes was calculated and presented in the statement of earnings as if the Company’s earnings were fully taxable.  The amount of income taxes payable, if any, is determined after utilizing the Company’s NOLs, including its pre-emergence bankruptcy NOLs.  Under American Institute of Certified Public Accountants Statement of Position 90-7, Financial Reporting by Entities in Reorganization Under the Bankruptcy Code (“SOP 90-7”), the tax benefit for the utilization of these pre-emergence bankruptcy NOL carry forwards must be recognized as a reduction of intangibles rather than a reduction of the provision for taxes in the statement of earnings.

The Company adopted the provisions of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109 (“FIN 48”) on November 1, 2007.  There was no additional reserve for uncertain tax positions recognized as a result of adoption of FIN 48.  During the three and six months ended April 30, 2008, the Company recognized $0 and $27,000, respectively, of income tax expense related to the increase in reserves for uncertain tax positions.  The total reserve as of April 30, 2008 was $27,000.  The entire amount of the reserve related to uncertainties regarding income tax nexus with various states in which the Company operates.  Included in the reserve is $8,000 of estimated interest and penalties.  The total amount of the reserve has increased the Company’s effective tax rate, and would therefore decrease the effective tax rate if removed.

Estimated interest and penalties related to potential underpayment of income taxes are classified as a component of tax expense in the consolidated statement of earnings.  The Company does not expect the amount of reserves for uncertain tax positions to change significantly in the next twelve months.  The Company does not anticipate that the total reserve for uncertain tax positions will significantly change due to the settlement of audits and the expiration of statutes of limitations within the next twelve months.

The Company files a consolidated federal income tax return in the United States Federal jurisdiction and files various combined and separate tax returns in several state and local jurisdictions. With limited exceptions, the Company is no longer subject to U.S. Federal, state and local tax examinations by tax authorities for fiscal years ending prior to November 1, 2004.  There is no statute of

13

limitations for assessments related to jurisdictions where the Company may have nexus but has chosen not to file an income tax return.

The Company had a federal net operating loss carry forward at October 31, 2007 of approximately $20.9 million.  This amount is the remaining utilizable carry forward following the application of a limit due to an ownership change under Internal Revenue Code Section 382 that occurred during the fourth quarter of fiscal year 2006.  This carry forward is available to offset a portion of taxes payable in future years.  If not used, this carry forward will expire in the years 2009 through 2025.  Approximately $7.6 million of this carry forward will expire, if unused, during the next five years ending October 31, 2012.  The Company also has $115,000 of alternative minimum tax credit carry forwards that do not have expiration dates.  Even though the Company has substantial federal net operating loss carry forwards, any income may still be subject to U.S. and State alternative minimum taxes.

The Company has recorded a full valuation allowance against its net deferred tax asset based on its belief that it was more likely than not that the asset would not be realized in the future.  Although this determination was made in a prior fiscal year, it is still applicable as of April 30, 2008, and the Company will continue to assess the need for a full valuation allowance in future quarters.  Under SOP 90-7, a substantial portion of any future reversal of the valuation allowance will first reduce any intangible assets and then be credited directly to additional paid-in capital.  After the exhaustion of pre- emergence bankruptcy NOLs, approximately $2.3 million of the valuation allowance is related to post-bankruptcy NOLs and would be available to reduce the provision for taxes in the statement of earnings and, thereafter, $778,000 related to excess stock option tax deductions would be recognized as additional paid-in capital when realized in the Company’s income tax return.

10.                               Litigation

The Company is also subject to certain claims and lawsuits that have been filed in the ordinary course of business.  From time to time, the Company initiates lawsuits against others to enforce patents or to seek collection of debts in the ordinary course of business.  It is management’s opinion that the settlement of all litigation arising in the ordinary course of business would not have a material effect on the financial position, results of operations or liquidity of the Company.

11.                               Severance Costs

On April 30, 2008, the Company implemented a second Reduction-In-Force (RIF) that terminated the employment of nine employees to allow better management of operating expenses.  In the second quarter 2008, the Company also terminated a relationship with a foreign distributor.  As a result of these actions, the Company accrued a total of $172,000 in severance costs for the quarter ended April 30, 2008 which consisted of $169,000 of cash severance and $3,000 of medical benefits.  For the six months ended April 30, 2008, total severance costs of $366,000 were incurred.

The following table reconciles second quarter activity for accrued severance expenses:

14

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

The Company, through its Medical Graphics Corporation subsidiary, designs and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics and New Leaf brand and trade names.  These cardiorespiratory diagnostic systems have a wide range of applications in healthcare, wellness and health and fitness.  Revenues consist of equipment and supply sales as well as service revenues.  Equipment and supply sales reflect sales of non-invasive cardiorespiratory diagnostic equipment and aftermarket sales of peripherals and supplies.  Service revenues consist of revenues from extended service contracts, non-warranty service visits and additional training.

The Company has developed and had planned to launch the new generation Platinum Elite cardiorespiratory system in its hospital and physician office product line at the end of the fourth quarter of fiscal 2007.  This new system, the first significant introduction since 1998, has several new features and technological advancements, and will enable Angeion to achieve new manufacturing synergies.  Angeion delayed the product launch until the latter half of the second quarter of fiscal 2008 while it fine-tuned the technical performance and finalized regulatory certifications related to this system.  The Platinum Elite is now available and being distributed into the marketplace.

In addition, the Company recently introduced the Physician Office Program which is a targeted sales and marketing campaign directed at the diagnosis of Chronic Obstructive Pulmonary Disease (COPD).  The program is expected to raise awareness of COPD and increase demand for the Company’s non-invasive pulmonary function diagnostic systems.

Total revenue for the second quarter of 2008 was $7.3 million, a decrease of 26.5% from $10.0 million in 2007.  Operating expenses for the second quarter of 2008 were $4.3 million, a decrease of 1.3% from the same period in 2007.  Net loss for the three months ended April 30, 2008 was $373,000, or $0.09 per share, compared to net income of $453,000, or $0.11 per diluted share, for the same period in 2007.

Total revenue for the six months ended April 30, 2008 was $14.8 million, a decrease of 28.0% from $20.6 million in 2007.  Operating expenses for the period were $8.7 million, a decrease of 0.8% from the same period in 2007.  Net loss for the six months ended April 30, 2008 was $1.0 million, or $0.26 per share, compared to net income of $942,000, or $0.22 per diluted share, for the same period in 2007.

At the end of the second quarter, the Company implemented actions to further reduce operating expenses in future quarters by eliminating nine employees.  These reductions are incremental to the Reduction-In-Force implemented during the first quarter of 2008.  As a result of both reductions, the Company expects, on an annualized basis, to save $1.5 million in personnel-related expenses.  Headcount for the Company as of April 30, 2008 now stands at 122 employees compared to 139 at the beginning of the fiscal year.

15

Results of Operations

The following table contains selected information from the Company’s consolidated statements of earnings, expressed as a percentage of revenues:

The following paragraphs discuss the Company’s performance for the three and six month periods ending April 30, 2008 and 2007:

Revenue

Total revenue for the three and six months ended April 30, 2008, decreased by 26.5% and 28.0%, respectively, compared to the same period in 2007.  The decrease in revenue of $2.7 million for the three month period ended April 30, 2008 was caused in part by a $1.9 million decrease in revenues from clinical research customers due to the early conclusion of our large clinical research customer’s trials.  Sales to this customer accounted for only 2.7% of revenue in the three months ending April 30, 2008 compared to 23.8% of revenue for the same period in 2007.

The decrease in revenue of $5.8 million for the six month period ended April 30, 2008 was caused in part by a $4.2 million decrease in revenues due to the early conclusion of our large clinical research customer’s trials.  For the six months ending April 30, 2008, sales to this customer accounted for 4.7% of revenue compared to 23.8% of revenue for the same period in 2007.

Excluding sales to this customer, revenue for the three and six months ended April 30, 2008 decreased by 6.2% and 9.9%, respectively, compared to the same period in 2007.  The decrease in revenue, exclusive of the clinical research project, is attributable to the delay in the launch of the new Platinum Elite cardiorespiratory product until the latter half of the 2008 second quarter.

Gross Margin

Gross margin percentage for the three and six month period ended April 30, 2008 increased to 52.4% and 51.4% of revenue, respectively, compared to 50.5% and 50.2%, respectively, for the same

16

period in 2007.  Gross margin percentage for the three and six month periods increased slightly as a result of cost reductions implemented in the first and second quarters of 2008, higher margin service revenues as an increased percentage of total revenue and less product sold to our large clinical research customer, which carried a lower product margin.

Selling and Marketing

Selling and marketing expenses decreased to $2.3 million and $4.7 million, respectively, for the three and six month periods ended April 30, 2008 from $2.5 million and $5.0 million for the same periods in 2007.

The $224,000, or 8.8%, decrease for the three month period ended April 30, 2008 is primarily due to a drop in payroll, benefit and travel expenses.  On January 31, 2008, the Company implemented a Reduction-In-Force (RIF) that terminated the employment of eight employees, mostly in sales and marketing, to allow better management of operating expenses.  Savings related to the RIF were $153,000 for the second quarter.  On April 30, 2008, the Company terminated an additional nine employees.  As a result of this action, the Company accrued $65,000 of severance and medical benefits for those employees related to the selling and marketing function.  In addition, travel expense decreased by $72,000 and commissions decreased by $32,000 as a result of the challenging sales environment.

The $328,000, or 6.6%, decrease for the six month period is primarily due to a drop in payroll, benefit and travel expenses.  In addition to the RIF savings of $153,000, travel and customer support expenses also decreased by $149,000 and, as a result of lower than expected sales, commissions dropped $221,000 for the six months ended April 30, 2008 compared to the same period in 2007.  These expense savings were partially offset by additional stock-based compensation of $55,000 incurred in 2008 compared to an immaterial expense in 2007.  In addition, severance expense for marketing personnel incurred in the fiscal 2008 second quarter were $65,000.

General and Administrative

For the three months ended April 30, 2008, general and administrative expenses increased by $162,000, or 18.3%, compared to the same period in 2007.  For the six months ended April 30, 2008, general and administrative expenses increased by $320,000, or 15.6%, compared to the same period in 2007.

For the three months ended April 30, 2008, professional fees increased by $70,000 compared to the same period in 2007.  The majority of the expenses incurred were additional audit fees related to the Company’s year-end audit with our predecessor audit firm.  Non-cash stock-based compensation expense of $60,000 was incurred during the three months ended April 30, 2008 compared to an immaterial expense in the second quarter of 2007.  Directors’ fees also increased by $32,000 for the second quarter of 2008 as the Company added an additional Board member and held additional meetings.

For the six months ended April 30, 2008, non-cash stock-based compensation expense of $129,000 was incurred versus an immaterial expense for the same period in 2007.  Personnel and recruiting expenses increased by $92,000 versus 2007.  In addition, directors’ fees as well as higher depreciation expense from purchases of information technology equipment caused an increase of $74,000 in general and administrative costs compared to the prior year.

17

Research and Development

Research and development expenses for the three and six months ended April 30, 2008 were $708,000 and $1.3 million, respectively, compared to $693,000 and $1.4 million, respectively, for the same period in 2007.

Project expenses associated with new products decreased by $49,000, or 19.7%, for the six months ended April 30, 2008 compared to the same period in 2007 due to early completion of certain new project testing.  All other related personnel, travel and consulting costs did not change materially as compared to the prior-year period.  The Company’s current new product development initiatives include products targeted for hospital intensive care units, cardiology, dietary, asthma, allergy and primary care physicians, health and fitness club professionals, as well as international markets.  These new products are currently completing clinical evaluation and are planned for release during fiscal 2008.

Amortization of Intangibles

Amortization of developed technology was $182,000 and $364,000, respectively, for the three and six months ended April 30, 2008 compared to $190,000 and $385,000, respectively, for the same period in 2007.  The decrease is attributable to reductions in the valuation of developed technology as the Company utilized its pre-emergence bankruptcy net operating loss (“NOL”) carry forwards in 2007, which lowered the 2008 carrying values.

Interest Income

Interest income for the three months ended April 30, 2008 decreased $5,000 from $47,000 to $42,000 versus 2007 as a drop in market interest rates during the second quarter more than offset higher cash balances.

For the six months ended April 30, 2008, interest income increased $22,000 to $105,000 compared to the same period in 2007 due to higher cash balances held during the first half of 2008.

Provision for Income Taxes

Under Generally Accepted Accounting Principles, the Company is required to present the provision for taxes as if it were fully taxable in accordance with SOP 90-7.  With respect to the actual payment of taxes, however, the Company has utilized its pre-emergence bankruptcy NOLs in the calculation of its income taxes payable but is still required to pay U.S. and State alternative minimum taxes (“AMT”) in certain jurisdictions, even though it has substantial federal and state NOL carry forwards.  During the quarter ended April 30, 2008, the Company did not use any tax benefits related to pre-emergence bankruptcy NOLs.  During 2007, the Company used tax benefits of $318,000 related to pre-emergence bankruptcy NOLs.  These benefits have been recorded as a reduction of intangible assets.    See note 9 to the consolidated financial statements, “Income Taxes,” in this Form 10-Q for additional discussion of the accounting for income taxes and the use of pre-emergence bankruptcy NOLs.

Liquidity and Capital Resources

The Company has financed its liquidity needs over the last several years through revenue generated by the operations of its wholly owned subsidiary, Medical Graphics Corporation.

The Company had cash and cash equivalents of $7.1 million and working capital of $11.5 million as of April 30, 2008.  During the first half of fiscal 2008, the Company reported a net loss of $1.0 million,

18

however, cash flow from operating activities improved by $283,000, primarily due to the collections of accounts receivable for $2.1 million on the large sales volumes that occurred in the fourth quarter of fiscal 2007.  In addition, the add-back of non-cash expenses totaling $828,000 for depreciation, amortization and stock-based compensation improved the Company’s cash flow.

Partially offsetting these cash inflows were an increase in inventory levels of $820,000, a decrease in accounts payable balances of $460,000 and a decrease in employee compensation payables of $415,000.  Inventory levels have steadily increased as the Company prepares for new product launches during fiscal 2008.  Employee compensation accruals decreased due to a lower bonus accrual for 2008 year to date performance compared to 2007 and because employee bonuses are paid out during the first quarter of the fiscal year.

For the six months ended April 30, 2008, the Company used $113,000 in cash for the purchase of property and equipment.  The Company has no material commitments for capital expenditures for the remainder of fiscal year 2008.

The Company believes that its liquidity and capital resource needs for fiscal year 2008 will be met through its current cash and cash equivalents as well as cash flows resulting from operations.  As a result of the termination of seventeen employees during the first six months of 2008, the Company expects to save $1.5 million in salaries and other payroll expenditures on an annualized basis going forward.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

None.

Item 4.  Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures

Management, with the participation of the Company’s chief executive officer, Rodney A. Young, and chief financial officer, William J. Kullback, has evaluated the effectiveness of the design and operation of the disclosure controls and procedures, as defined in Rules 13a-15(e) under the Securities Exchange Act of 1934, as of the end of the period covered by this report.  Management has concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports that the Company files under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that the disclosure controls are also effective to ensure that information required to be disclosed in the Company’s Exchange Act reports is accumulated and communicated to management, including the chief executive officer and principal accounting officer, to allow timely decisions regarding required disclosure.

(b) Changes in Internal Controls.

There have been no significant changes in internal control over financial reporting that occurred during the second fiscal quarter of 2008 that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

Item 4T.  Controls and Procedures.

None.

19

PART II – OTHER INFORMATION

Item 1.  Legal Proceedings.

The Company is subject to certain claims and lawsuits that have been filed in the ordinary course of business.  From time to time, the Company brings suit against others to enforce patent rights or to collect debts in the ordinary course of business.  Management believes that the settlement of all litigation would not have a material effect on the results of operations or liquidity of the Company.

Item 1A. Risk Factors

The most significant risk factors applicable to the Company are described in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended October 31, 2007.  There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.  Defaults Upon Senior Securities.

None.

Item 4.  Submission of Matters to a Vote of Security Holders.

Our Annual Meeting of Shareholders was held on May 20, 2008.  Of the 4,089,803 share of common stock outstanding and entitled to vote at the meeting as of April 4, 2008, 3,485,631 shares were present, either in person or by proxy.  The following describes the matters considered by the shareholders at the Annual Meeting, as well as the results of the Votes cast at the meeting.

Proposal 1:  To elect seven directors of the Company to serve until the next Annual Meeting of Shareholders or until their respective successors have been elected and qualified.

Proposal 2:  To approve an amendment to the Angeion Corporation 2007 Stock Incentive Plan to increase by 300,000 the shares authorized for issuance under the Plan.

20

Item 5.  Other Information.

Change-in-Control Agreement with William J. Kullback

As described in Angeion’s Form 8-K dated March 17, 2008, the Company and William J. Kullback have now entered into a Change-in-Control Agreement dated as of June 15, 2008, upon the successful completion of his initial 90 day employment period.  Under the Change in Control Agreement, if Mr. Kullback’s employment is terminated during a period of eighteen months following a Change-in-Control of the Company (i) by the Company other than for Cause or death, or (ii) by Mr. Kullback for Good Reason (as these terms are defined in the Agreement), then he will be entitled to a lump-sum payment equal to 1.5 times his annual base salary.  In addition to this amount, Mr. Kullback would be entitled to a fee for out-placement services in an amount equal to 10% of his salary or $20,000 and the Company would continue to pay its portion of his health insurance for twelve months as if he were still employed.  If this termination without cause were to occur, the amount payable to Mr. Kullback pursuant to his Change-in-Control Agreement would be approximately $320,000.

Copies of the Employment Agreement dated March 17, 2008 and the Change-in-Control Agreement between the Company and Mr. Kullback are attached as Exhibits 10.1 and 10.2.

Item 6.  Exhibits.

21

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

22